1. >
  2. Investors
  3. >
  4. Regulated Information
  5. >
  6. Press Releases – Reg...

PRESS RELEASES

Found 286 Results
Page 2 of 29

Onxeo announces the success of its Rights Issue with €9.7 million raised


This transaction will accelerate the development of the Company and its portfolio and extend its financial horizon to the end […]

04/12/2021


Onxeo to Present New Preclinical Data at AACR 2021


Confirming the effect of AsiDNA™ on resistance to KRAS inhibitors Introducing OX400, a new generation of PARP interfering cancer drug […]

Tags: ,

04/08/2021


B-Smart – Interview of Judith Greciet, CEO of Onxeo


Watch the interview (in French)

03/26/2021


Onxeo will publish its annual results on April 21, 2021


The Annual General Meeting will be held on June 10, 2021 Paris (France), March 24, 2021 – 6 pm CET […]

Tags:

03/24/2021


Onxeo Launches a Rights Issue to accelerate its R&D programs


This transaction will secure the financing of the strategy and the resources necessary to achieve key clinical milestones until at […]

03/10/2021



Onxeo publishes Letter to Shareholders and provides update on its developments


Paris (France), February 2, 2021 – 9 pm CET – Onxeo S.A. (Euronext Growth: ALONX; Nasdaq First North: ONXEO), a […]

02/02/2021


Onxeo Obtains Non-Dilutive Financing of 5 Million Euros in the Form of State Guaranteed Loans


This financing extends the Company’s cash horizon to the 3rd quarter of 2022   Paris (France), January 28, 2021 – […]

01/28/2021


Onxeo to Attend Key Investor and Scientific Conferences


Paris (France), January 11, 2021 – 7:00 am CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

01/11/2021


2020 – Full-year report on the liquidity contract


2020 Full-year report on the liquidity contract

01/08/2021


Page 2 of 29